MedTrace Logo

Study of Safety and Efficacy of the Percutaneous Reduction of Mitral Valve Regurgitation in Heart Failure Patients

NCT00787293 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-02-14

No results posted yet for this study

Summary

Improvement in heart failure with moderate to severe mitral regurgitation using a percutaneously delivered implantable device.

Conditions

Interventions

DEVICE

PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant

Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein, anterior interventricular vein.

Sponsors & Collaborators

  • Duke University

    collaborator OTHER

  • Medifacts International Corporation

    collaborator INDUSTRY

  • Viacor

    lead INDUSTRY

Principal Investigators

  • Stefan Sack, Md, PhD · Klinikum Schwabing, Staedtisches Klinikum Muenchen GmbH

  • Rainer Hoffmann, MD · R-WTH Universitätsklinikum Aachen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-11-30
Completion
2015-11-30

Countries

  • Belgium
  • Czechia
  • Germany
  • Netherlands
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00787293 on ClinicalTrials.gov